Zelira Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
8
- Stock Symbol
-
ZLD
- Investments
-
2
- Share Price
-
$0.69
- (As of Wednesday Closing)
Zelira Therapeutics General Information
Description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
Contact Information
Website
www.zeliratx.com
Formerly Known As
Zelda Therapeutics, Gleneagle Gold
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
ASX
Primary Office
- Level 3
- 101 Saint Georges Terrace
- Perth, Western Australia 6000
- Australia
+61 1300 000 000
Zelira Therapeutics Timeline
Zelira Therapeutics Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.69 | $0.67 | $0.57 - $2.18 | $7.78M | 11.3M | 7.59K |
Zelira Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2023 30-Jun-2023 | FY 2022 30-Jun-2022 | FY 2021 30-Jun-2021 |
|---|---|---|---|---|
| EV | 7,278 | 11,475 | 5,181 | 35,135 |
| Revenue | 202 | 1,116 | 322 | |
| EBITDA | (3,796) | (8,538) | (5,989) | |
| Net Income | (3,747) | (8,656) | (6,374) | |
| Total Assets | 22,433 | 25,935 | 29,577 | |
| Total Debt | 290 | 345 | 414 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Zelira Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Zelira Therapeutics Patents
Zelira Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021215262-A1 | Composition and method for treating chronic pain | Pending | 12-Jun-2020 | 0000000000 | |
| CA-3186718-A1 | Composition and method for treating chronic pain | Pending | 12-Jun-2020 | 0000000000 | |
| EP-4164628-A1 | Composition and method for treating chronic pain | Pending | 12-Jun-2020 | 0000000000 | |
| AU-2020901947-A0 | Composition and method for treating chronic pain | Pending | 12-Jun-2020 | ||
| US-20230218566-A1 | Composition and method for treating chronic pain | Pending | 12-Jun-2020 | A61K31/352 |
Zelira Therapeutics Executive Team (7)
Zelira Therapeutics Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000 000000 | Self | Co-Founder & Board Member | 000 0000 |
Zelira Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Zelira Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Zelira Therapeutics Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ilera Therapeutics | 01-Dec-2019 | 0000000000 | Pharmaceuticals | 00000 000 | |
| Gleneagle Gold | 30-Oct-2016 | Merger/Acquisition | Gold Mining | 00000 000 |